supported by the National Natural Science Foundation of China(No.62172288).
Objective To investigate the impact of CYP2C19 gene polymorphism on clopidogrel reactivity and its association with longterm clinical outcome in patients with coronary heart disease(CHD)undergoing percutaneous coronar...
supported by the CAMS Innovation Fund for Medical Sciences (CIFMS, 2016-I2M-1-009);Twelfth Five-Year Planning Project of the Scientific and Technological Department of China (2011BAI11B02);National Natural Science Foundation of China (No 81670415)。
Background Proton pump inhibitors(PPIs) are recommended by the latest guidelines to reduce the risk of bleeding in acute myocardial infarction(AMI) patients treated with dual antiplatelet therapy(DAPT). However, previ...
Dual antiplatelet therapy(DAPT)with aspirin and clopidogrel has been widely used after percutaneous coronary intervention(PCI).The bleeding complications caused by it cannot be ignored and the incidence is as high as ...
A 67-year-old woman with a history of diabetes mellitus and smoking was admitted to our hospital with chest pain for one month. Her resting electrocardiogram and serial troponin I measurements were normal. As the coro...
Background There is great debate on the possible adverse interaction between proton pump inhibitors (PPIs) and clopidogrel. In ad- dition, whether the use of PPIs affects the clinical efficacy of ticagrelor remains ...
Antiplatelet therapy with clopidogrel is widely used as a preventive strategy in patients with acute coronary syn- drome, particularly after stent implantation.Diverse mani- festations of clopidogrel hypersensitivity ...
Background Despite the proven benefits of clopidogrel combined aspirin therapy for coronary artery disease (CAD), CAD patients with metabolic syndrome (MS) still tend to have coronary thrombotic events. We aimed t...
Background Low responsiveness to clopidogrel (LRC) is associated with increased risk of ischemic events. This study was aimed to explore the feasibility of tailored antiplatelet therapy according to the responsivene...
Background Triple therapy(TT)with vitamin K-antagonists(VKA),aspirin and clopidogrel is the recommended antithrombotic treatment following percutaneous coronary intervention with stent implantation(PCI-S)in patients w...